A Panobinostat Presurgery

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2012

Conditions
Recurrent Glioblastoma
Interventions
DRUG

panobinostat

Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Duke University

OTHER